Summary Study objective: To assess whether asthmatic children may generate sufficient peak inspiratory flow through the Novolizer s
Introduction
For many years the inhalation of drugs has been a proven measure in the treatment of bronchial asthma 1 and chronic obstructive pulmonary disease. 2 In that way and in contrast to systemic treatment, the ratio of desired effects to adverse reactions can be improved considerably by inhalation. 1, 2 At present, pressurised metered dose inhalers (pMDIs) are the most commonly used device for the inhalation of drugs targeted to the lungs. Until recently, pMDIs contained chlorofluorocarbon (CFC) propellants. In search of alternatives, new propellants for CFC-free pMDIs as well as dry powder inhalers (DPI) containing no propellants at all have been developed.
Both from an ecological and medical point of view, DPIs have certain advantages over the pMDIs. The optimal use of pMDIs requires the coordination of the actuation with appropriate timing of inspiration. Several studies showed that only approximately 25% of adult patients are able to perform a correct inhalation manoeuvre. 3, 4 Coordination of actuation and inhalation is, however, not necessary for a dry powder inhaler. Even children as young as 8 years are able to use a DPI correctly. 5 Moreover, when inhaling an active substance by means of a DPI, there is no cold sensation of propellants, nor are surface-active substances inhaled. On the other hand, conventional DPIs offer no possibility for operator control of a correct inhalation. However, delivery of the drug dose into the lung depends on a sufficient inspiratory flow generated by the patient. 6 Therefore a device with a low to medium resistance might be of importance, especially for children and for an effective use during an acute asthma attack.
The Novolizer s is an example of an alternative non-propellant inhalation device: a multiple dose dry powder inhaler (MDPI). The patient inhales micronised active substance and carrier from the device, i.e. the powder is transported to the lungs by a stream of inhaled air. The Novolizer s contains up to 200 doses in a replaceable cartridge and can therefore be characterised as a refillable, multidose, multi-use device. Recently a Novolizer s delivering 200 mg of budesonide per dose has been registered in the EU for the treatment of adults and children of 6 years and older. The device has a low to medium airflow resistance (0.0260 kPa 0.5 min l -1
), which is illustrated in Fig. 1 Clinical studies demonstrated the therapeutic efficacy and safety of the Novolizer s in adult patients with asthma and COPD equivalent to the Turbuhaler s . 8, 9 Deposition of budesonide in the lungs (assessed by gamma scintigraphy) achieved via the Novolizer s was at least as much as via the Turbuhaler s when both devices were used at similar flow rates. 10 In vitro and in vivo flow rate dependency was found for the Novolizer s as for most other DPIs. 7, 11 . The trigger threshold of the Novolizer is between 35 and 50 l/min. The Novolizer s is easy to use, which makes it particularly useful for the paediatric population. In addition, its visual and acoustic feedback mechanisms are of particular value for the use in children, since for the first time direct evidence is provided for parents and other supervisors indicating that the inhalation manoeuvre was carried out indeed in the right manner (Fig. 2) .
Currently, little data exist about the applicability of the Novolizer s in paediatric patients. Therefore the objectives of this study were to assess whether children aged 4-11 years with stable bronchial asthma are able to generate sufficient peak inspiratory flow through the Novolizer s (PIF-N) and to assess whether these children can effectively operate this device after adequate instruction. In order to further characterise the study population, FEV 1 and peak inspiratory flow (PIF) were assessed and correlated to each other, to the PIF-N and to the children's age. 
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Patients and methods
The trial was designed as an open label multicentre study. As the Novolizer s was used with an empty cartridge, no medication was administered for the purpose of this trial.
Patients
Male or female children of 4-11 years could be included, provided that they had a history and current clinical evidence of bronchial asthma of any origin, and they either had a baseline FEV 1 o90% predicted or were pre-treated with inhaled steroids up to a maximum of 400 mg budesonide per day (or equivalent daily dosages of other inhaled steroids). There was no specific recommendation regarding use or non-use of concomitant medication; however, restrictions of concomitant medication before lung function testing were as follows: short-acting b-agonists and anticholinergics for 6 h, long-acting b-agonists, inhaled corticosteroids, leukotriene antagonists, theophylline, cromoglycate, or nedocromil for 12 h. Patients who had experienced an exacerbation of asthma during the previous week were excluded. When conducting the trial, Novolizer s products (such as the budesonide delivering product) were not yet indicated for the use in children below 12 years. In fact, none of the participating children had prior experience with this device, i.e. they may be characterised as Novolizer-naives, as confirmed by the prior medication records.
Inhalation
After the assessment of FEV 1 and PIF, the investigators concisely instructed the children in the correct use of the Novolizer s . Each patient inhaled three times 12, 20 through the Novolizer s device in order to assess the PIF-N. For these measurements patients were instructed to inhale as fast and hard as they could through the Novolizer s . No test or learning inhalations were allowed and no child had prior experience with the Novolizer s . The PIF-N and simultaneously the ability to operate the Novolizer s was assessed with a device connected in series with the lung function diagnostic equipment. This construction allowed the assessment of the actual peak inspiratory flow values achieved through the PIF-N. Hence, an individually prenumbered device was put into a specially designed airtight box which was linked in series with the Jaeger MasterScope s pneumotachograph (Jaeger, Hochdorf, Germany; pneumotachographic principle of flow measurement, used to calculate the volumes for spirometry). The Jaeger MasterScope s is a well-known and validated device, certified according to ISO 9001, CE-as well as FDA-registered, and fulfils criteria of the German and European law on medicinal devices. 13 Analogue procedures for the assessment of inspiratory flow were used by other authors. 12, 22, 24 The experimental circumstances required a fixed position of the device in the box and a fixed position of the box. Furthermore, the box partially covered the mouth piece of the Novolizer s diminishing the length of it. The airtight box that covered the Novolizer s was constructed in a manner not influencing the flow assessments. Each airtight box used in this trial was tested and the system box-Novolizer-Masterscope was validated (Sofotec, Frankfurt am Main, Germany) prior to providing the centres with the equipment.
For the purpose of quality assurance, the investigators judged, for each inhalation through the Novolizer s , whether the inhalation manoeuvre was performed according to the instruction. This allowed the exclusion of erroneous measurements. The decision whether the trigger threshold had been overcome was based on the occurrence of both, the acoustic and visual indicator of the device.
Ethics
Study protocol and patient's informed consent were reviewed by an Independent Ethics Committee. Parents and patients' informed and written consents were obtained prior to enrolment. The trial was carried out in accordance with the laws and guidelines current at that time: the German law on Medical Devices, the principles of the Declaration of Helsinki, and the Guideline for Good Clinical Practice.
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Statistics
All statistical evaluations and analyses were performed using SASt 8.2. The analysis of the study was performed in a descriptive and exploratory manner. The three documented FEV 1 measurements were condensed to the individual maximum value (best of three), PIF and PIF-N measurements were analysed primarily as individual means; individual maximum, minimum and 1st attempt values are also presented. Appropriate analyses by age group, analyses of correlation, and linear regressions between variables were performed additionally. The sample size considerations were based on a former study with an Allergospasmin s Novolizer s (study code 3187, data on file ) and yielded a precision of estimations of about 20 l/min for PIF and about 3 l/min for PIF-N with 120 patients based on 95% 2-sided confidence limits.
Results
The study was performed at 7 centres in Germany. A total of 138 patients were screened, for 137 of them PIF measurements were available, representing the ITT population. Ethnic origin of patients was Caucasian for 97.8% and other for 3/137 (2.2%) of patients. Most patients (92, 67.2%) already had experience with spirometry procedures. A summary of demography and baseline characteristics is provided in Table 1 .
PIF-N data from one child are not available due to computer problems, thus, 136 children provided PIF-N data. All except 5 patients were able to overcome the trigger threshold, i.e. 131 of 136 (96.3%). All 5 children who were unable to overcome the trigger threshold were in the age class 4-5 years ð5=32 ¼ 15:6%Þ: Most patients, namely 116 (85.3%) were successful in overcoming the trigger threshold in all three attempts; 10 (7.4%) patients were successful at two attempts, and 5 (3.7%) patients were successful at only 1 attempt. In addition to the 116 children who inhaled successfully at all 3 attempts, 6 children inhaled only twice and both attempts were successful; another 4 children had a successful first attempt, but, failed at one of the following. Thus, 126 Table 1 Demographics and baseline lung function data from all patients with available PIF.
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Variable
All patients 4-5 yr 6-7 yr 8-9 yr 10-11 yr (92.6%) of the children had a successful first attempt. Successful inhalation manoeuvres were accompanied by mean PIF-N measurements of 72.0 l/min (range: 37.8-130.2 l/min). A total of 373 attempts was included in this calculation. The 26 inhalation manoeuvres which failed overcoming the trigger threshold were accompanied by mean PIF-N measurements of 35:6712:4 l=min: For the 131 patients who passed the trigger threshold at least once the PIF-N (maximum of all attempts) was 77.4 l/min (43.8-130.2 l/min). Table 2 summarises the descriptive statistics of PIF and PIF-N for all patients with at least one PIF measurement and by age group. No coughing was provoked by the inhalation.
PIF increased on average with age, which was not observed for PIF-N (Fig. 3) . The group 10-11 years had higher PIF than the group 8-9 years, whereas no such pattern was observed for PIF-N.
Pearson correlation coefficients were calculated and regression analyses investigating the correlation between age, FEV 1 , and FEV 1 %-predicted on the one hand and PIF and PIF-N on the other hand as well as between PIF and PIF-N were performed ( Table 3 ). In the interpretation of PIF-N results it has to be considered that no further increase was Fig. 4 ).
ARTICLE IN PRESS
Discussion
With DPIs, efficient release and deposition of medication dependsFamong other factorsFon an adequate PIF. Although it was shown that the PIF as a sole variable is not sufficient to judge the quality of an inhalation, 14 drug deposition in the respiratory tract is to a large extent determined by an adequate PIF. Also the fine particle fraction, a major factor for peripheral drug deposition in the lung, is substantially flow dependent. In a study evaluating lung deposition of radiolabelled budesonide inhaled through the Novolizer s or Turbuhaler s at different flow rates, a significant correlation between lung deposition and PIF was found, 11 while the ratio between peripheral and central zone deposition as the oropharyngeal deposition was not influenced by a change in PIF. However, the Turbuhaler s had a significantly higher oropharyngeal deposition. Similar effects were noticed in studies with other devices. 15 As PIF through a device is higher when the device's airflow resistance is lower, 16 an inhalation device with a low to medium airflow resistance such as the Novolizer s might improve the drug deposition in the respiratory tract. An increase in inspiratory flow has been shown to increase the proportion of respirable particles, and instructing patients to inhale ''forcefully and deeply'' rather than ''deeply'' has proved to be more effective. 17 Our patients were instructed to inhale ''as fast and hard as they could''. Therefore we conclude that patients who had overcome the threshold inhaled with sufficient acceleration.
In our study PIF and PIF-N were analysed in stable asthmatic children (either FEV 1 predicted o90% or pre-treated with low-dose inhaled steroids). Twothirds of the children had experience with inhalers, and most of them had experience with powder inhalers. For all, it was the first time ever inhaling through the Novolizer s . Furthermore, after the instruction to utilise the Novolizer s , they were given no opportunity to train the inhalation.
Bronsky et al. 18 assessed inspiratory flow rates in 32 asthmatic children (mean age 9.6 years, range7-11). The mean PIF (through spirometer alone) was 154 l/min. This compares well with the mean PIF (mean out of three attempts) in this study, 148 l/ min, when the same age group is considered (7) (8) (9) (10) (11) years, n ¼ 85). Thus, our methodology is in line with the published data, which can be regarded as an external validation. We found a correlation of PIF with age; however, children above 8 years of age, always being clearly above the device's trigger threshold, showed only little further increase in PIF-N with age. This confirms previous findings, where PIFs through another powder inhaler device named Diskus s or Accuhaler s were investigated and a non-linear relationship between age and PIF-Diskus was found. 19 The relationship tended to be almost linear up to 8 years after which the curve reached a plateau.
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Compared to other inhalation devices, the percentage difference between mean PIF and mean PIF through the device (PIF-N) was with 46% (mean out of three attempts) rather low, reflecting the fact that the Novolizer s has a low to medium air flow resistance (0.0260 kPa 0.5 min l -1 ). Engel et al. 20 performed PIF measurement through the Turbuhaler s in 101 adult asthmatic patients with a mean FEV 1 predicted of 68%. That study showed a stronger difference between PIF without and with Turbuhaler s (261 vs 59 l/min), i.e. a 75% reduction of inspiratory flow. In fact the Turbuhaler s has a high air flow resistance (0.0367 kPa 0.5 min l -1 ). A percentage of 96% of the children succeeded to overcome the individual trigger threshold of the Novolizer s . Only 5 children, all younger than 6 years, were unable to overcome the trigger threshold. The mean PIF-N rates achieved by children aged 4-12 years were distinctly above the technical trigger threshold. This trigger threshold was designed at a PIF-N, which has demonstrated a sufficient lung deposition for drugs delivered by the Novolizer s ; 7, 11 it is in the flow range of 35-50 l/min. Another study showed that children of 6 years and older are usually able to achieve a PIF 440 l/min. 5 Compared to studies with the Turbuhaler s , where a considerable proportion of children even older than 6 years failed to achieve a PIF 430 l/min through the Turbuhaler s , 21, 22 all children in our study, whose PIF-N was o35 l/min, were younger than 6 years.
An important aspect of the Novolizer s compared to other inhalers is that it provides an indication for an adequate inhalation flow. The visual feedback (changing from green to red) and the acoustic feedback (''click'') which follow adequate inhalation manoeuvres offer the opportunity to protect against unintentional underdosing. Thus, the Novolizer s is one of the first inhalation devices that offers parents and caregivers the possibility to control correct inspiratory flow manoeuvres of their children, which makes the Novolizer s especially useful for paediatric patients.
PIF depends upon multiple factors such as inspiratory musculature or airway diameter. At least from paediatric cystic fibrosis patients it is known that PIF does not correlate with predicted values of expiratory flow. 23 In our study, the best, though by far imperfect predictor for PIF, was FEV 1 In summary, data available suggest that common measures of expiratory lung function are poor predictors of inspiratory performance. In general, the PIF-N data measured in our study appear to realistically describe the inspiratory performance of asthmatic children. The fact that 5 of the 32 children younger than 6 years failed to correctly inhale should not lead to generally exclude children of this age group from treatment with the Novolizer s device because the feedback mechanism allows to distinguish between an unsuccessful and a successful attempt. Our study indicates that 27 of the 32 (84%) children younger than 6 years and all 104 children above 6 years with stable bronchial asthma are able to generate a sufficient peak inspiratory flow through the Novolizer s to overcome the trigger threshold and to operate effectively this device after adequate instruction.
